Antibody Drug Conjugate News and Research

RSS

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."

18 Jan 2023

UKB resident awarded the C. E. Alken Prize for outstanding scientific uro-oncological research

Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), was awarded the C. E. Alken Prize in recognition of his outstanding scientific uro-oncological work.

30 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Comprehensive analysis outlines the potential toxicities of antibody drug conjugates

Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients.

21 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Multiple ischemic strokes and pulmonary embolism found in COVID-19 patient

In a new study, researchers described a case of a patient with acute respiratory failure and ischemic stroke.

17 Oct 2022

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.

13 Sep 2022

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone.

14 Jul 2022

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.

From Spirea 14 Jun 2022

At US hospitals, a drug mix-up is just a few keystrokes away

More than four years ago, Tennessee nurse RaDonda Vaught typed two letters into a hospital's computerized medication cabinet, selected the wrong drug from the search results, and gave a patient a fatal dose.

29 Apr 2022

Study demonstrates multinuclear MRI is sensitive to functional pulmonary changes in the follow up of patients hospitalized with COVID-19

In this study, researchers subjected patients to a pulmonary 1H and 129Xe MRI protocol at 6, 12, 25, and 50 weeks after hospitalization.

11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

Massachusetts General Hospital researchers have identified for the first time how a highly aggressive form of breast cancer can evade one of the most powerful and effective drugs used to treat it, reporting their findings in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2021

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.

23 Jul 2021

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

How do you kill tumor cells that can't be targeted? Get their more susceptible neighbors to help.

22 Jun 2021

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.

From Iksuda Therapeutics 22 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021